Zhitong Finance App News, Yasheng Pharmaceutical-B (06855) issued an announcement. Four clinical studies of the company's three key varieties were selected for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, and one of them received an oral report. These three key varieties are the first and only third-generation BCR-ABL inhibitor approved for marketing in China, olebatinib (HQP1351; trade name: Nelick), the Bcl-2 selective inhibitor APG-2575, and the FAK/ALK/ROS1 triple inhibitor APG-2449.
The annual ASCO annual conference is the most important and authoritative academic exchange event in the field of oncology in the world. It will showcase current cutting-edge clinical oncology research results and cancer treatment techniques in the world. This year's ASCO Annual Conference will be held from May 31, 2024 to June 4 (US local time) in a combination of online and offline formats at the McCormick Convention Center in Chicago, Illinois, USA.